Immunocore Holdings plc Increase (Decrease) in Contract with Customer, Liability
Immunocore Holdings plc (IMCR) reported Increase (Decrease) in Contract with Customer, Liability of -$292.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$146.00K.
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$146.00K.
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$144.00K.
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$146.00K.
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for fiscal 2025 was -$387.00K.
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for fiscal 2024 was -$1.00K.
- Immunocore Holdings plc increase (decrease) in contract with customer, liability for fiscal 2023 was -$8.01M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$292.00K 10-Q · filed 2026-08-06 | -$436.00K derived: sum of 3 quarters · filed 2026-08-06 | -$582.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$146.00K 10-Q · filed 2026-05-06 | -$290.00K derived: sum of 2 quarters · filed 2026-05-06 | -$436.00K derived: sum of 3 quarters · filed 2026-05-06 | -$533.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$290.00K derived: sum of 2 quarters · filed 2026-02-25 | -$387.00K derived: sum of 3 quarters · filed 2026-08-06 | -$387.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | -$146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$243.00K derived: sum of 2 quarters · filed 2026-08-06 | -$243.00K 10-Q · filed 2025-11-06 | -$243.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$97.00K 10-Q · filed 2026-08-06 | -$97.00K derived: sum of 3 quarters · filed 2026-08-06 | -$98.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | -$1.00K derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.00K 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | -$8.01M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |